“Kynurenine switch” and obesity

Aim. To assess the concentrations of bacterial and eukaryotic metabolites mainly involved in indole, kynurenine, and serotonin pathways of tryptophan metabolism in a cohort of patients with obesity. Materials and methods. Using high-performance liquid chromatography with mass spectrometric detection, the concentrations of several serum metabolites, such as kynurenine, kynurenic acid, anthranilic acid, xanthurenic acid, quinolinic acid, 5-hydroxyindole-3-acetate, tryptamine, serotonin, indole-3-lactate, indole-3-acetate, indole-3- butyrate, indole-3-carboxaldehyde, indole-3-acrylate, and indole-3-propionate, were analyzed in a cohort of obese patients compared with healthy volunteers.

Results. It was found that serum levels of tryptophan metabolites of microbial and eukaryotic origin were significantly increased in obese patients. Therefore, the concentration of kynurenine in the blood serum in obese patients was 2,413 ± 855 nmol / l, while in healthy volunteers of the same age group, the level of kynurenine in the blood serum was 2,122 ± 863 nmol / l. In obese patients, two acids formed due to kynurenine metabolism; the concentrations of kynurenic and quinolinic acids were increased in the blood serum. The concentration of kynurenic acid in the blood serum in obese patients was 21.1 ± 9.26 nmol / l, and in healthy patients, it was 16.8 ± 8.37 nmol / l. At the same time, the level of quinolinic acid in the blood serum in obese patients was 73.1 ± 54.4 nmol / l and in healthy volunteers – 56.8 ± 34.1 nmol / l. Normally, the level of quinolinic acid is 3.4 times higher than the concentration of kynurenic acid, and in case of obesity, there is a comparable increase in these acids in the blood serum.

From indole derivatives, mainly of microbial origin, the concentrations of indole-3-lactate, indole-3-butyrate, and indole-3-acetate were significantly increased in the blood serum of obese patients. In obese patients, the serum concentration of 5-hydroxyindole-3-acetate was elevated to 74.6 ± 75.8 nmol / l (in healthy volunteers – 59.4 ± 36.6 nmol / l); indole-3-lactate – to 523 ± 251 nmol / l (in healthy volunteers – 433 ± 208 nmol / l); indole-3-acetate – to 1,633 ± 1,166 nmol / l (in healthy volunteers – 1,186 ± 826 nmol / l); and indole-3-butyrate – to 4.61 ± 3.31 nmol / l (in healthy volunteers – 3.85 ± 2.51 nmol / l).

Conclusion. In case of obesity, the utilization of tryptophan was intensified by both the microbiota population and the macroorganism. It was found that obese patients had higher concentrations of kynurenine, quinolinic and kynurenic acids, indole-3-acetate, indole-3-lactate, indole-3-butyrate, and 5-hydroxyindole-3-acetate. Apparently, against the background of increased production of proinflammatory cytokines by adipocytes in obese patients, the “kynurenine switch” was activated which contributed to subsequent overproduction of tryptophan metabolites involved in the immune function of the macroorganism. 

1. Comai S., Bertazzo A., Brughera M., Crotti S. Tryptophan in health and disease. Adv. Clin. Chem. 2020; 95: 165–218. DOI: 10.1016/bs.acc.2019.08.005.

2. Dehhaghi M., Kazemi Shariat P.H., Guillemin G.J. Microorganisms, tryptophan metabolism, and kynurenine pathway: a complex interconnected loop influencing human health status. Int. J. Tryptophan Res. 2019; 12: 1178646919852996. DOI: 10.1177/1178646919852996.

3. Sas K., Szabo E., Vecsei L. Mitochondria, oxidative stress and the kynurenine system, with a focus on ageing and neuroprotection. Molecules. 2018; 23 (1): 191. DOI: 10.3390/molecules23010191.

4. Agus A., Planchais J., Sokol H. Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host. Microbe. 2018; 23 (6): 716–724. DOI: 10.1016/j.chom.2018.05.003.

5. Katoh A., Uenohara K., Akita M., Hashimoto T. Early steps in the biosynthesis of NAD in Arabidopsis start with aspartate and occur in the plastid. Plant Physiol. 2006; 141 (3): 851–857. DOI: 10.1104/pp.106.081091.

6. Sundaram G., Lim C.K., Brew B.J., Guillemin G.J. Kynurenine pathway modulation reverses the experimental autoimmune encephalomyelitis mouse disease progression. J. Neuroinflammation. 2020; 17 (1): 176. DOI: 10.1186/s12974-020-01844-y.

7. Ferreira F.S., Schmitz F., Marques E.P., Siebert C., Wyse A.T. Intrastriatal quinolinic acid administration impairs redox homeostasis and induces inflammatory changes: prevention by kynurenic acid. Neurotox. Res. 2020; 38 (1): 50–58. DOI: 10.1007/s12640-020-00192-2.

8. Moffett J.R., Arun P., Puthillathu N., Vengilote R., Ives J.A., Badawy A.A., Namboodiri A.M. Quinolinate as a marker for kynurenine metabolite formation and the unresolved question of NAD(+) synthesis during inflammation and infection. Front. Immunol. 2020; 11: 31. DOI: 10.3389/fimmu.2020.00031.

9. Wolowczuk I., Hennart B., Leloire A., Bessede A., Soichot M., Taront S., Caiazzo R., Raverdy V., Pigeyre M., Guillemin G.J., Allorge D., Pattou F., Froguel P., Poulain-Godefroy O. Tryptophan metabolism activation by indoleamine 2,3-dioxygenase in adipose tissue of obese women: an attempt to maintain immune homeostasis and vascular tone. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2012; 303 (2): R135–R143. DOI: 10.1152/ajpregu.00373.2011.

10. Han Q., Robinson H., Cai T., Tagle D.A., Li J. Structural insight into the inhibition of human kynurenine aminotransferase I/glutamine transaminase. K. J. Med. Chem. 2009; 52 (9): 2786–2793. DOI: 10.1021/jm9000874.

11. Jin U.H., Lee S.O., Sridharan G., Lee K., Davidson L.A., Jayaraman A., Chapkin R.S., Alaniz R., Safe S. Microbiome-derived tryptophan metabolites and their aryl hydrocarbon receptor-dependent agonist and antagonist activities. Mol. Pharmacol. 2014; 85 (5): 777–788. DOI: 10.1124/mol.113.091165.

12. Sitkin S., Pokrotnieks J. Gut microbiota as a host defender and a foe: the 2 faces of commensal Bacteroides thetaiotaomicron in inflammatory bowel disease. Inflamm. Bowel Dis. 2019; 25 (6): e71. DOI: 10.1093/ibd/izy377.

13. Brandacher G., Hoeller E., Fuchs D., Weiss H.G. Chronic immune activation underlies morbid obesity: is IDO a key player? Curr. Drug Metab. 2007; 8 (3): 289–295. DOI: 10.2174/138920007780362590.

14. Tashiro Y., Toyofuku M., Nakajima-Kambe T., Uchiyama H., Nomura N. Bicyclic compounds repress membrane vesicle production and Pseudomonas quinolone signal synthesis in Pseudomonas aeruginosa. FEMS Microbiol. Lett. 2010; 304 (2): 123–130. DOI: 10.1111/j.1574-6968.2010.01897.x.

15. Pernomian L., Duarte-Silva M., de Barros Cardoso C.R. The aryl hydrocarbon receptor (AHR) as a potential target for the control of intestinal inflammation: insights from an immune and bacteria sensor receptor. Clin. Rev. Allergy Immunol. 2020; 59 (3): 382–390. DOI: 10.1007/s12016-020-08789-3.

16. Li X., Lu C., Fan D., Lu X., Xia Y., Zhao H., Xu H., Zhu Y., Li J., Liu H., Xiao C. Human umbilical mesenchymal stem cells display therapeutic potential in rheumatoid arthritis by regulating interactions between immunity and gut microbiota via the aryl hydrocarbon receptor. Front. Cell Dev. Biol. 2020; 8: 131. DOI: 10.3389/fcell.2020.00131.

17. Meng D., Sommella E., Salviati E., Campiglia P., Ganguli K., Djebali K., Zhu W., Walker W.A. Indole-3-lactic acid, a metabolite of tryptophan, secreted by Bifidobacterium longum subspecies infantis is anti-inflammatory in the immature intestine. Pediatr. Res. 2020; 88 (2): 209–217. DOI: 10.1038/s41390-019-0740-x.